HUP9801384A3 - Clostridium perfringens vaccine - Google Patents

Clostridium perfringens vaccine

Info

Publication number
HUP9801384A3
HUP9801384A3 HU9801384A HUP9801384A HUP9801384A3 HU P9801384 A3 HUP9801384 A3 HU P9801384A3 HU 9801384 A HU9801384 A HU 9801384A HU P9801384 A HUP9801384 A HU P9801384A HU P9801384 A3 HUP9801384 A3 HU P9801384A3
Authority
HU
Hungary
Prior art keywords
clostridium perfringens
perfringens vaccine
vaccine
clostridium
perfringens
Prior art date
Application number
HU9801384A
Other languages
English (en)
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Publication of HU9801384D0 publication Critical patent/HU9801384D0/hu
Publication of HUP9801384A2 publication Critical patent/HUP9801384A2/hu
Publication of HUP9801384A3 publication Critical patent/HUP9801384A3/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/08Clostridium, e.g. Clostridium tetani
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
HU9801384A 1997-06-20 1998-06-19 Clostridium perfringens vaccine HUP9801384A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP97201888 1997-06-20

Publications (3)

Publication Number Publication Date
HU9801384D0 HU9801384D0 (en) 1998-08-28
HUP9801384A2 HUP9801384A2 (hu) 1999-03-29
HUP9801384A3 true HUP9801384A3 (en) 2001-11-28

Family

ID=8228464

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9801384A HUP9801384A3 (en) 1997-06-20 1998-06-19 Clostridium perfringens vaccine

Country Status (17)

Country Link
US (1) US6610300B1 (hu)
EP (1) EP0892054B1 (hu)
JP (1) JP4234232B2 (hu)
KR (1) KR19990007306A (hu)
CN (2) CN1215729A (hu)
AT (1) ATE346931T1 (hu)
AU (1) AU743498B2 (hu)
BR (1) BR9802361A (hu)
CA (1) CA2235445A1 (hu)
DE (1) DE69836520T2 (hu)
DK (1) DK0892054T3 (hu)
ES (1) ES2276448T3 (hu)
HU (1) HUP9801384A3 (hu)
NZ (1) NZ330749A (hu)
PT (1) PT892054E (hu)
TW (1) TWI221847B (hu)
ZA (1) ZA985393B (hu)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9521568D0 (en) * 1995-10-20 1995-12-20 Lynxvale Ltd Delivery of biologically active polypeptides
FR2768747B1 (fr) * 1997-09-19 2000-12-01 Pasteur Institut Acides nucleiques, cellules recombinantes, et procede de preparation de compositions immunogenes
US7780961B2 (en) * 2001-05-03 2010-08-24 Actogenix N.V. Self-containing Lactococcus strain
EP1560935A2 (en) * 2002-11-15 2005-08-10 VIB vzw Self-containing lactobacillus strain
US8748126B2 (en) 2005-11-29 2014-06-10 Actogenix N.V. Induction of mucosal tolerance to antigens
PL2004220T3 (pl) * 2006-03-30 2015-11-30 Zoetis Services Llc Sposoby i kompozycje do szczepienia drobiu
EP2007420B1 (en) * 2006-04-17 2013-03-06 Intervet International B.V. Recombinant attenuated clostridium organisms and vaccine
KR20090081389A (ko) * 2006-11-20 2009-07-28 인터벳 인터내셔널 비.브이. 백신의 제조를 위한 클로스트리디움 퍼프린젠스 c 형 박테리아의 용도
EP3351268B1 (en) 2007-01-25 2020-08-05 Intrexon Actobiotics NV Treatment of immune disease by mucosal delivery of antigens
EP2164862B1 (en) * 2007-06-08 2015-07-22 Australian Poultry CRC Pty Ltd Clostridial toxin netb
RU2550271C2 (ru) * 2007-09-14 2015-05-10 Санофи Пастер Байолоджикс Ко. Иммуногенная композиция для лечения или профилактики clostridium difficile, способ ее получения и способ индукции иммунного ответа к c. difficile
KR101825439B1 (ko) * 2016-04-15 2018-02-05 배재대학교 산학협력단 염산 처리에 의한 그람양성 박테리아 고스트의 제조 방법
CN110882384B (zh) * 2019-12-17 2024-01-26 天康生物制药有限公司 猪流行性腹泻-猪梭菌性肠炎二联亚单位的口服疫苗及制备方法
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB958574A (en) * 1959-11-23 1964-05-21 Wellcome Found Clostridium perfringens ª‰-toxoid vaccines
SE7809880L (sv) * 1978-09-20 1980-03-21 Zemlyakova Valentina Porfiriev Vaccin for profylax och behandling av clostridiosis hos djur och fjederfe
GB2283020B (en) * 1992-05-20 1996-05-01 Secr Defence Clostridium perfringens vaccines
US5538851A (en) * 1993-12-22 1996-07-23 Institut Pasteur And Cneva Primers for the amplification of genes coding for the enterotoxin and the lecithinase of Clostridium perfringens and their application to the determination of the presence and numeration of these bacteriae
GB9522611D0 (en) 1995-11-03 1996-01-03 Brooks Holdings Ltd Improvements in and relating to a security closure for a door opening
GB9605222D0 (en) * 1996-03-12 1996-05-15 Secr Defence Clostridium perfringens epsilon toxin vaccines

Also Published As

Publication number Publication date
EP0892054A1 (en) 1999-01-20
US6610300B1 (en) 2003-08-26
NZ330749A (en) 1999-10-28
BR9802361A (pt) 2000-01-11
EP0892054B1 (en) 2006-11-29
ATE346931T1 (de) 2006-12-15
CA2235445A1 (en) 1998-12-20
PT892054E (pt) 2007-02-28
HU9801384D0 (en) 1998-08-28
ZA985393B (en) 1999-02-17
ES2276448T3 (es) 2007-06-16
AU743498B2 (en) 2002-01-24
DK0892054T3 (da) 2007-04-02
CN101914145A (zh) 2010-12-15
JPH11103872A (ja) 1999-04-20
CN1215729A (zh) 1999-05-05
AU7308798A (en) 1998-12-24
KR19990007306A (ko) 1999-01-25
DE69836520T2 (de) 2007-06-06
HUP9801384A2 (hu) 1999-03-29
DE69836520D1 (de) 2007-01-11
TWI221847B (en) 2004-10-11
JP4234232B2 (ja) 2009-03-04

Similar Documents

Publication Publication Date Title
AU2103797A (en) Clostridium perfringens vaccines
GB9712347D0 (en) Vaccine
GB9718901D0 (en) Vaccine
IL136446A0 (en) Vaccine
GB9711990D0 (en) Vaccine
GB9726555D0 (en) Vaccine
GB9720585D0 (en) Vaccine
HK1083736A1 (zh) 針對頑固性梭狀芽孢杆菌疾病的被動免疫
DE69804447D1 (en) Lithographisches system
PL335973A1 (en) Connection
IL121454A0 (en) Internet-telephone interface system
HUP9801384A3 (en) Clostridium perfringens vaccine
GB9705926D0 (en) Improved document completion
PL325324A1 (en) Heasting system
ZA982763B (en) Vaccines
GB2330039B (en) Integrated wireline-wireless system
GB9700448D0 (en) Easy reach
GB9715487D0 (en) Mearsurement system
GB9700014D0 (en) Interface
GB9717423D0 (en) Vaccine
GB9718902D0 (en) Vaccine
GB9720982D0 (en) Vaccine
GB9702920D0 (en) Vaccines
ZA983357B (en) Prop
GB9215655D0 (en) Clostridium perfringens vaccines

Legal Events

Date Code Title Description
GB9A Succession in title

Owner name: INTERVET INTERNATIONAL B.V., NL

Free format text: FORMER OWNER(S): AKZO NOBEL N.V., NL

FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished